查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1993048

生物可吸收植入市場：按材料、產品類型、應用和最終用戶分類－2026-2032年全球市場預測

Bioresorbable Implants Market by Material Type, Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年生物可吸收植入市場價值為60.9億美元，預計到2026年將成長至65.4億美元，複合年成長率為7.42%，到2032年將達到100.7億美元。

主要市場統計數據
基準年 2025 60.9億美元
預計年份：2026年 65.4億美元
預測年份 2032 100.7億美元
複合年成長率 (%) 7.42%

生物可吸收植入代表了醫療設備設計的模式轉移。這些植入物所採用的材料不僅能夠發揮治療功能，而且在完成其治療目的後，還能安全地分解並被人體吸收。這些技術融合了材料科學、聚合物化學和器械工程，可提供臨時的結構支撐、局部藥物傳輸或促進組織再生的生物活性支架。在臨床實踐中，盡可能減少異物在體內長期存在的解決方案變得越來越重要，而生物可吸收植入正在從介入心臟病學到整形外科重組和眼科藥物輸送等眾多專科領域得到廣泛應用。

臨床醫生和醫療設備研發人員越來越認同實證醫學方法，該方法旨在平衡分解動力學與生物癒合時間線。法律規範日趨完善，以適應生物可吸收技術，生產和滅菌製程也不斷最佳化，以維持材料的完整性和臨床性能。同時，聚合物化學家、生物醫學工程師和外科醫生之間的跨學科合作正在加速設計改進，以應對治療過程中耐久性和後續可預測吸收方面的挑戰。

從概念到臨床應用，不僅需要令人信服的臨床結果，還需要可重複的生產流程、可擴展的供應鏈以及清晰的醫保報銷理由。當相關人員評估各種機會時，臨床需求、材料特性和商業化準備之間的策略互動，決定了哪些生物可吸收解決方案能夠從臨床實驗應用過渡到標準治療。本報告對這些因素進行了深入分析和整合，旨在為策略規劃和投資決策提供支援。

新的科學、臨床和製造趨勢正在迅速改變生物可吸收植入解決方案的開發和應用。

生物可吸收植入領域正因技術進步與臨床需求的融合而煥然一新，其設計、測試和應用方式也隨之改變。聚合物化學的創新催生了諸如脂肪族聚酯等具有可調分解速率和機械性能的材料，使得植入物能夠更精準地適應組織癒合過程。此外，積層製造和微加工技術使得建構具有複雜形狀和孔隙梯度結構成為可能，從而實現可控的吸收動力學並增強組織整合。這些技術的結合催生了新一代植入，它們在關鍵的恢復階段既具有臨時性，又能保持功能上的穩定性。

近期關稅政策的變化對生物可吸收植入製造商的供應鏈韌性、籌資策略和產業計畫有何影響？

關鍵市場關稅政策的變化可能對生物可吸收植入製造商的供應鏈、籌資策略和產業計畫產生重大影響。隨著2025年關稅調整的實施，醫療設備供應商和零件製造商正在重新審視其全球採購結構，以降低成本波動風險，並確保關鍵原料和成品的持續供應。如果關稅增加進口聚合物、基材或滅菌服務的到貨成本，企業正在考慮將近岸外包、供應商多元化和垂直整合作為應對策略。

將材料科學、臨床應用、產品類型和最終用戶趨勢連結起來的詳細細分分析，為開發和商業化決策提供支援。

關鍵的細分市場洞察揭示了決定產品適用性、臨床應用和研發重點的關鍵技術和商業性差異。材料選擇仍然是至關重要的因素，聚己內酯、聚乙醇酸、聚乳酸和聚乳酸-羥基乙酸共聚物各自具有不同的分解特性、機械性能和加工要求，這些都會影響醫療設備的設計選擇和臨床適應症。設計人員必須根據所需的吸收時間表和宿主組織反應來選擇聚合物，以確保在整個治療期間保持結構完整性。

區域趨勢正在影響全球主要市場的監管路徑、臨床導入模式和生產重點。

區域趨勢對臨床應用、監管路徑和生產投資有顯著影響，並在關鍵區域造成了不同的策略挑戰。美洲地區臨床試驗活動集中，心血管和整形外科等專科領域的手術量也高。完善的健保報銷系統能夠加速成熟醫療設備的市場准入，從而為此趨勢提供了支持。此外，國內供應鏈的考量和政策調整也促進了本地生產能力的提升，以減輕跨境中斷和關稅的影響。

生物可吸收植入領域產業領導者的競爭和組織要求：卓越的製造能力、監管策略和臨床證據的產生。

生物可吸收植入領域的競爭動態是由成熟的醫療設備製造商、專業聚合物研發公司以及專注於特定臨床應用的Start-Ups新創公司共同推動的。產業領導企業憑藉涵蓋材料化學、器材工程和臨床證據生成等方面的綜合能力脫穎而出，而新興企業往往在尚未滿足需求的細分臨床領域中競爭。隨著大型企業尋求透過新型可吸收夥伴關係拓展產品組合，以及小規模創新者尋求更廣泛的市場進入，策略合作和授權協議正變得越來越普遍。

製造商加速採用的具體策略重點：協調材料創新、可擴展製造和臨床證據的創建。

產業領導企業應採取協作策略，將材料創新、臨床檢驗和供應鏈韌性相結合，從而將技術潛力轉化為永續的商業性成功。優先考慮具有可調分解特性和可預測力學性能的材料組合，並投資於將聚合物性能與臨床癒合時間聯繫起來的轉化研究。能夠預測宿主反應和分解產物的可靠的臨床前項目將降低監管風險，並增強臨床醫生的信心。

採用透明、多方面的研究途徑，結合專家訪談、材料技術分析、監管審查以及對競爭格局和供應鏈的評估。

本研究結合了對臨床專家、材料科學家、醫療設備工程師和採購經理的訪談，並嚴格審查了監管申報文件、公開的臨床試驗註冊資訊和同行評審文獻，從而整體情況了生物可吸收植入。在方法論上，調查方法強調將各領域專家的定性見解與聚合物性能、分解動力學和器械動態的技術分析進行交叉檢驗，以確保商業性應用基於材料科學和臨床實際情況。

臨床、製造和經濟需求的整合決定了哪些生物可吸收植入創新能夠獲得持續的臨床和商業性成功。

生物可吸收植入處於材料科學、臨床需求和衛生經濟學的戰略交匯點，為改善患者預後並減輕器械的長期負擔提供了一條途徑。此類器械的未來發展取決於研發人員如何有效地將聚合物科學轉化為經臨床檢驗的器械，製造商如何確保強大且高品質的生產能力，以及支付方和醫療服務提供者如何認可並報銷其主導的價值。那些整合了深厚的技術專長、嚴謹的臨床專案和靈活的價值鏈策略的機構將能夠引領這一領域。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物可吸收植入市場：依材料類型分類

  • 聚己內酯
  • 聚乙醇酸
  • 聚乳酸
  • 聚乳酸-羥基乙酸共聚物

第9章：生物可吸收植入市場：依產品類型分類

  • 藥物輸送系統
    • 水凝膠
    • 微球
  • 固定裝置
    • 別針
    • 盤子
    • 擰緊
  • 鷹架
    • 骨支架
    • 組織框架
  • 縫合線
    • 編織
    • 單絲

第10章：生物可吸收植入市場：依應用領域分類

  • 心血管系統
    • 修補補丁
    • 支架
    • 血管移植
      • 冠狀動脈移植
      • 周邊血管移植
  • 牙科
    • 骨移植材料
    • 電影
  • 眼科
    • 藥物輸送
    • 鷹架
    • 縫合線
  • 整形外科
    • 骨再生
      • 接枝
      • 油灰
      • 鷹架
    • 骨折固定
      • 別針
      • 盤子
      • 擰緊
    • 脊椎融合手術
      • 籠
      • 桿
      • 擰緊

第11章：生物可吸收植入市場：以最終用戶分類

  • 門診手術中心
  • 診所
  • 醫院

第12章：生物可吸收植入市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：生物可吸收植入市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：生物可吸收植入市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國生物可吸收植入市場

第16章：中國生物可吸收植入市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Acumed LLC
  • Arthrex, Inc.
  • B. Braun Melsungen AG
  • BASF SE
  • BioPolymer GmbH & Co. KG
  • Bioretec Ltd.
  • Boston Scientific Corporation
  • ConMed Corporation
  • Corbion NV
  • Evonik Industries AG
  • Inion Oy
  • Integra LifeSciences Corporation
  • Johnson & Johnson Services, Inc.
  • KLS Martin Group
  • Medtronic plc
  • Meril Life Sciences
  • NuVasive, Inc.
  • Orthofix Medical Inc.
  • Orthomed SAS
  • RTI Surgical Holdings, Inc.
  • Smith & Nephew plc
  • Stryker Corporation
  • Teleflex Incorporated
  • Tepha, Inc.
  • Xtant Medical Holdings, Inc.
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-1A1A064C0211

The Bioresorbable Implants Market was valued at USD 6.09 billion in 2025 and is projected to grow to USD 6.54 billion in 2026, with a CAGR of 7.42%, reaching USD 10.07 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.09 billion
Estimated Year [2026] USD 6.54 billion
Forecast Year [2032] USD 10.07 billion
CAGR (%) 7.42%

Bioresorbable implants represent a paradigm shift in medical device design, where materials engineered to perform a therapeutic function are designed to safely degrade and be absorbed by the body after serving their purpose. These technologies blend materials science, polymer chemistry, and device engineering to deliver temporary structural support, localized drug delivery, or biologically active scaffolding that promotes native tissue regeneration. As clinical practice increasingly prioritizes solutions that minimize long-term foreign body presence, bioresorbable options are advancing across multiple specialties, from cardiovascular interventions to orthopedic reconstruction and ophthalmic drug delivery.

Clinicians and device developers are converging on an evidence-driven approach that balances the kinetics of degradation with the biological timeline of healing. Regulatory pathways have matured to accommodate resorbable technologies, while manufacturing and sterilization processes have been optimized to maintain material integrity and clinical performance. Concurrently, cross-disciplinary collaborations among polymer chemists, biomedical engineers, and surgeons are accelerating design iterations that address durability during the therapeutic window and predictable absorption thereafter.

Transitioning from concept to clinical adoption requires not only compelling clinical outcomes but also reproducible manufacturing, scalable supply chains, and clear reimbursement narratives. As stakeholders evaluate opportunities, the strategic interplay of clinical need, material properties, and commercialization readiness defines which resorbable solutions will move from investigational use to standard of care. This report offers an incisive synthesis of those forces to inform strategic planning and investment decisions.

Emerging scientific, clinical, and manufacturing dynamics that are rapidly transforming the development and adoption of bioresorbable implant solutions

The bioresorbable implant landscape is being reshaped by converging technological advances and clinical imperatives that are changing how devices are conceived, tested, and adopted. Innovations in polymer chemistry are producing materials such as aliphatic polyesters with tunable degradation rates and mechanical profiles, enabling devices that match tissue healing timelines more precisely. Additive manufacturing and microfabrication techniques now permit complex geometries and porosity gradients that enhance tissue integration while controlling resorption kinetics. Together, these advances enable a new generation of implants that are purposefully transient yet functionally robust during critical phases of recovery.

Clinically, the shift toward minimally invasive procedures and outpatient pathways has elevated demand for implants that reduce long-term complications and secondary interventions. Surgeons increasingly embrace devices that support biological healing without leaving permanent hardware, particularly in patient populations where lifelong implants pose risks or complicate imaging and future interventions. At the same time, regulatory frameworks and clinical trial designs have adapted to address device biodegradation, host response, and long-term safety, which streamlines pathways for well-characterized materials and clearly defined performance endpoints.

Economic and operational transformations are also influential. Contract manufacturing organizations and component suppliers are investing in specialized processing capabilities for bioresorbable polymers, while payers and health systems are evaluating total cost of care benefits associated with reduced revision rates. The net effect is a market environment that rewards integrated approaches combining proven materials, scalable manufacturing, and robust clinical evidence, driving rapid maturation of resorbable implant offerings.

How recent tariff policy changes are reshaping supply chain resilience, sourcing strategies, and commercial planning for bioresorbable implant manufacturers

Tariff policy shifts in major markets have the potential to materially influence supply chains, sourcing strategies, and commercial planning for manufacturers of bioresorbable implants. In the wake of tariff adjustments implemented in 2025, device suppliers and component manufacturers have reassessed global procurement footprints to mitigate cost volatility and maintain continuity of critical raw materials and finished goods. Where tariffs raise landed costs for imported polymers, substrates, or sterilization services, firms have evaluated nearshoring, supplier diversification, and vertical integration as strategic responses.

The practical impact extends beyond unit cost. Increased tariffs can lengthen lead times and complicate inventory strategies, prompting manufacturers to increase safety stocks or qualify alternate materials and suppliers. For technology developers, higher cross-border costs incentivize local production of high-value components and may accelerate investments in domestic processing capacity for polymers such as polylactic acid derivatives. Regulatory approvals and quality control systems must keep pace to ensure that rapid supplier changes do not compromise device performance or traceability.

Payers and providers also respond to tariff-driven price shifts by scrutinizing reimbursement pathways and comparative value. In some cases, clinical adoption timelines have been extended while health systems assess whether higher acquisition costs are offset by reductions in long-term complications or reoperation rates. Ultimately, resilient commercial strategies emphasize supply chain transparency, multiple qualified suppliers across geographies, and adaptive contract terms to absorb policy volatility while protecting access to innovative resorbable therapies.

In-depth segmentation analysis linking material science, clinical application, product typology, and end-user dynamics to inform development and commercialization choices

Key segmentation insights reveal critical technical and commercial differences that determine product fit, clinical applicability, and development priorities. Material selection remains foundational, with polycaprolactone, polyglycolic acid, polylactic acid, and polylactic-co-glycolic acid each offering distinct degradation profiles, mechanical characteristics, and processing requirements that influence device design choices and clinical indications. Designers must align polymer selection with the desired resorption timeline and host tissue response to ensure that structural integrity is retained for the required therapeutic window.

Application-driven segmentation highlights the diversity of clinical use cases. In cardiovascular applications, repair patches, stents, and vascular grafts present unique engineering and regulatory demands, where stents may include vascular scaffolds and grafts span coronary and peripheral indications. Dental applications are oriented around bone grafts and membranes that support dental regeneration and implantology. Ophthalmic needs focus on drug delivery vehicles, scaffolds, and sutures that interface with sensitive ocular tissues and require precise degradation control. Orthopedic applications encompass bone regeneration, fracture fixation, and spine fusion; within these, bone regeneration devices include grafts, putty, and scaffolds while fracture fixation leverages pins, plates, and screws and spine fusion employs cages, rods, and screws. Each application imposes distinct mechanical and biological constraints that guide R&D priorities.

Product-type segmentation further refines market opportunity, differentiating drug delivery systems, fixation devices, scaffolds, and sutures. Drug delivery approaches incorporate hydrogels and microspheres to enable localized therapeutic release, whereas fixation devices rely on pins, plates, and screws designed to carry load then resorb. Scaffolds bifurcate into bone scaffolds and tissue scaffolds that provide structural templates for regeneration. Sutures, whether braided or monofilament, must balance handling characteristics with predictable absorption. End-user segmentation across ambulatory surgical centers, clinics, and hospitals shapes purchasing behaviors, inventory needs, and adoption velocity, as institutional capabilities and procedural volumes influence device selection and implementation strategies.

Comparative regional dynamics shaping regulatory pathways, clinical adoption patterns, and manufacturing priorities across major global markets

Regional dynamics exert strong influence on clinical adoption, regulatory pathways, and manufacturing investments, creating distinct strategic imperatives across major geographies. The Americas exhibit concentrated clinical trial activity and significant procedural volumes in specialties such as cardiovascular and orthopedics, supported by established reimbursement frameworks that can accelerate market entry for devices with demonstrated outcomes. Domestic supply chain considerations and policy shifts also incentivize local manufacturing capabilities to reduce exposure to cross-border disruptions and tariff effects.

Europe, Middle East & Africa present a heterogeneous regulatory and healthcare landscape where device approval processes vary by jurisdiction and health technology assessment plays an outsized role in procurement decisions. Reimbursement pathways can be more conservative in parts of this region, promoting rigorous comparative-effectiveness evidence as a prerequisite for widespread adoption. Meanwhile, pockets of rapid adoption exist where clinicians and health systems prioritize minimally invasive and regenerative solutions, creating targeted opportunities for manufacturers able to navigate regional regulatory complexity and deliver compelling clinical value propositions.

Asia-Pacific is characterized by diverse markets ranging from highly advanced healthcare systems to rapidly developing ones, each with unique demands for affordability, scalability, and clinical outcomes. Manufacturing capacity in this region is expanding, and there is growing local demand for innovative implants that align with population health needs. Collaborations between local clinical centers and global developers are increasingly common, enabling both clinical validation and localized product adaptation to meet regulatory and procedural preferences in the region.

Competitive and organizational imperatives that define industry leaders in bioresorbable implants, including manufacturing excellence, regulatory strategy, and clinical evidence generation

Competitive dynamics in the bioresorbable implant sector are driven by a mix of established medical device manufacturers, specialized polymer developers, and agile startups focused on niche clinical applications. Leaders differentiate through integrated capabilities that span material chemistry, device engineering, and clinical evidence generation, while emerging players often compete on novel materials, innovative manufacturing approaches, or targeted clinical niches where unmet needs remain acute. Strategic partnerships and licensing arrangements are common as larger firms seek to augment portfolios with novel resorbable technologies and smaller innovators pursue broader market access.

Manufacturing competency is a critical competitive axis. Firms that invest in validated polymer processing, sterilization protocols compatible with resorbable substrates, and scalable assembly lines gain time-to-market advantages. Quality systems and regulatory know-how are equally important; companies that streamline submission pathways through robust preclinical characterization and early clinical collaborations can accelerate adoption. Additionally, supply chain resilience-including secured sources for medical-grade polymers and backup suppliers for critical components-constitutes a competitive moat against operational disruptions.

Commercial success also depends on clinical and payer engagement. Organizations that proactively generate real-world evidence, demonstrate reductions in reoperation rates or device-related complications, and articulate clear health-economic value propositions are better positioned to achieve reimbursement and clinician adoption. Finally, service models such as surgeon training, procedural support, and data-driven outcomes tracking can amplify market penetration and create differentiated value for customers.

Actionable strategic priorities for manufacturers to align material innovation, scalable manufacturing, and clinical evidence generation to accelerate adoption

Industry leaders should pursue a coordinated strategy that aligns materials innovation, clinical validation, and supply chain resilience to convert technological promise into sustainable commercial success. First, prioritize material portfolios that offer tunable degradation profiles and predictable mechanical performance, and invest in translational studies that link polymer properties to clinical healing timelines. Robust preclinical programs that anticipate host response and degradation byproducts will reduce regulatory risk and build clinician confidence.

Second, strengthen manufacturing and quality systems to support scale-up and to ensure consistent performance across lots. Qualification of multiple qualified suppliers for critical polymers and components, coupled with strategic nearshoring or regional manufacturing footprints, will reduce exposure to tariff-related cost shifts and shipping disruptions. Parallel investments in sterilization validation and packaging technologies tailored for resorbable substrates will preserve device integrity through the supply chain.

Third, design clinical development and market access plans that emphasize real-world evidence and health-economic outcomes. Align trial endpoints with payer requirements and clinician priorities to accelerate reimbursement conversations. Finally, cultivate collaborative commercialization models that include clinician education, procedure-level support, and outcomes monitoring to demonstrate comparative value. By integrating these strategic pillars-materials, manufacturing, clinical evidence, and commercial enablement-organizations can de-risk innovation pathways and accelerate adoption in diverse care settings.

Transparent multi-method research approach combining expert interviews, technical material analysis, regulatory review, and competitive and supply chain assessments

This research synthesizes primary interviews with clinical experts, material scientists, device engineers, and procurement leaders, combined with a rigorous review of regulatory filings, public clinical trial registries, and peer-reviewed literature to build a comprehensive view of the bioresorbable implant landscape. Methodological emphasis was placed on triangulating qualitative insights from subject-matter experts with technical analyses of polymer performance, degradation kinetics, and device biomechanics, ensuring that commercial implications are rooted in material science and clinical realities.

Analytical frameworks included segmentation mapping by material, application, product type, and end-user to surface differences in clinical requirements and adoption dynamics. Supply chain assessments evaluated manufacturing capacity, critical inputs, and policy exposure, including tariff sensitivities and logistical constraints. Competitive profiling assessed organizational capabilities across R&D, manufacturing, regulatory affairs, and commercialization, while regional analysis considered regulatory heterogeneity, payer environments, and clinical practice patterns.

Limitations are acknowledged: the dynamic nature of regulatory decisions and ongoing clinical research means that guidance is based on the best available evidence at the time of report preparation, and stakeholders should incorporate new clinical data and policy developments into decision models. Where appropriate, the research team employed conservative assumptions regarding adoption timelines and prioritized evidence from clinical studies and validated engineering characterizations rather than uncorroborated claims.

Synthesis of clinical, manufacturing, and economic imperatives that determine which bioresorbable implant innovations will achieve durable clinical and commercial success

Bioresorbable implants occupy a strategic intersection of materials science, clinical need, and healthcare economics, offering pathways to improve patient outcomes while reducing long-term device burden. The trajectory of this class of devices will be determined by how effectively developers translate polymer science into clinically validated devices, how manufacturers secure resilient and high-quality production capabilities, and how payers and providers recognize and reimburse demonstrated value. Those organizations that integrate deep technical expertise with rigorous clinical programs and adaptive supply chain strategies will be best positioned to lead.

As the healthcare ecosystem continues to emphasize value-based care and minimally invasive therapies, demand for resorbable solutions that lower reoperation rates and simplify patient management is likely to grow. However, realizing that potential requires coordinated investment in material optimization, regulatory preparedness, and real-world outcomes generation. Stakeholders who move decisively to align these elements will not only unlock clinical benefits but also capture commercial advantage in a landscape where predictability of performance and evidence of value are paramount.

In sum, bioresorbable implants present compelling opportunities for innovation-driven growth, yet success depends on disciplined execution across science, manufacturing, and clinical validation. Organizations that adopt an integrated approach will shape the next wave of resorbable therapies and set new standards for patient-centered device design.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bioresorbable Implants Market, by Material Type

  • 8.1. Polycaprolactone
  • 8.2. Polyglycolic Acid
  • 8.3. Polylactic Acid
  • 8.4. Polylactic-Co-Glycolic Acid

9. Bioresorbable Implants Market, by Product Type

  • 9.1. Drug Delivery Systems
    • 9.1.1. Hydrogels
    • 9.1.2. Microspheres
  • 9.2. Fixation Devices
    • 9.2.1. Pins
    • 9.2.2. Plates
    • 9.2.3. Screws
  • 9.3. Scaffolds
    • 9.3.1. Bone Scaffolds
    • 9.3.2. Tissue Scaffolds
  • 9.4. Sutures
    • 9.4.1. Braided
    • 9.4.2. Monofilament

10. Bioresorbable Implants Market, by Application

  • 10.1. Cardiovascular
    • 10.1.1. Repair Patches
    • 10.1.2. Stents
    • 10.1.3. Vascular Grafts
      • 10.1.3.1. Coronary Grafts
      • 10.1.3.2. Peripheral Grafts
  • 10.2. Dental
    • 10.2.1. Bone Grafts
    • 10.2.2. Membranes
  • 10.3. Ophthalmic
    • 10.3.1. Drug Delivery
    • 10.3.2. Scaffolds
    • 10.3.3. Sutures
  • 10.4. Orthopedic
    • 10.4.1. Bone Regeneration
      • 10.4.1.1. Grafts
      • 10.4.1.2. Putty
      • 10.4.1.3. Scaffolds
    • 10.4.2. Fracture Fixation
      • 10.4.2.1. Pins
      • 10.4.2.2. Plates
      • 10.4.2.3. Screws
    • 10.4.3. Spine Fusion
      • 10.4.3.1. Cages
      • 10.4.3.2. Rods
      • 10.4.3.3. Screws

11. Bioresorbable Implants Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Hospitals

12. Bioresorbable Implants Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bioresorbable Implants Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bioresorbable Implants Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Bioresorbable Implants Market

16. China Bioresorbable Implants Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Acumed LLC
  • 17.7. Arthrex, Inc.
  • 17.8. B. Braun Melsungen AG
  • 17.9. BASF SE
  • 17.10. BioPolymer GmbH & Co. KG
  • 17.11. Bioretec Ltd.
  • 17.12. Boston Scientific Corporation
  • 17.13. ConMed Corporation
  • 17.14. Corbion N.V.
  • 17.15. Evonik Industries AG
  • 17.16. Inion Oy
  • 17.17. Integra LifeSciences Corporation
  • 17.18. Johnson & Johnson Services, Inc.
  • 17.19. KLS Martin Group
  • 17.20. Medtronic plc
  • 17.21. Meril Life Sciences
  • 17.22. NuVasive, Inc.
  • 17.23. Orthofix Medical Inc.
  • 17.24. Orthomed S.A.S.
  • 17.25. RTI Surgical Holdings, Inc.
  • 17.26. Smith & Nephew plc
  • 17.27. Stryker Corporation
  • 17.28. Teleflex Incorporated
  • 17.29. Tepha, Inc.
  • 17.30. Xtant Medical Holdings, Inc.
  • 17.31. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIORESORBABLE IMPLANTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIORESORBABLE IMPLANTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BIORESORBABLE IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BIORESORBABLE IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY POLYCAPROLACTONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY POLYCAPROLACTONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY POLYCAPROLACTONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY POLYGLYCOLIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY POLYGLYCOLIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY POLYGLYCOLIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY POLYLACTIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY POLYLACTIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY POLYLACTIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY POLYLACTIC-CO-GLYCOLIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY POLYLACTIC-CO-GLYCOLIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY POLYLACTIC-CO-GLYCOLIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY HYDROGELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY HYDROGELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY HYDROGELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY MICROSPHERES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PLATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PLATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PLATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCREWS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCREWS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCREWS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY TISSUE SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY TISSUE SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY TISSUE SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY BRAIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY BRAIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY BRAIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY MONOFILAMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY MONOFILAMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY MONOFILAMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY REPAIR PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY REPAIR PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY REPAIR PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY CORONARY GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY CORONARY GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY CORONARY GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PERIPHERAL GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PERIPHERAL GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PERIPHERAL GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY MEMBRANES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY MEMBRANES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY MEMBRANES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE REGENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE REGENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE REGENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE REGENERATION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PUTTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PUTTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PUTTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY FRACTURE FIXATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY FRACTURE FIXATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY FRACTURE FIXATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY FRACTURE FIXATION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PLATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PLATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY PLATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCREWS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCREWS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCREWS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SPINE FUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SPINE FUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SPINE FUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SPINE FUSION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY CAGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY CAGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY CAGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY RODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY RODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY RODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCREWS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCREWS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY SCREWS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE REGENERATION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY FRACTURE FIXATION, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY SPINE FUSION, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS BIORESORBABLE IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE REGENERATION, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY FRACTURE FIXATION, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY SPINE FUSION, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE REGENERATION, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY FRACTURE FIXATION, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY SPINE FUSION, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA BIORESORBABLE IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE REGENERATION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY FRACTURE FIXATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY SPINE FUSION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE REGENERATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY FRACTURE FIXATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY SPINE FUSION, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE BIORESORBABLE IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE REGENERATION, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY FRACTURE FIXATION, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY SPINE FUSION, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST BIORESORBABLE IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE REGENERATION, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY FRACTURE FIXATION, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY SPINE FUSION, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA BIORESORBABLE IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE REGENERATION, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY FRACTURE FIXATION, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY SPINE FUSION, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC BIORESORBABLE IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. GLOBAL BIORESORBABLE IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY BONE REGENERATION, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY FRACTURE FIXATION, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY SPINE FUSION, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN BIORESORBABLE IMPLANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. GCC BIORESORBABLE IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 312. GCC BIORESORBABLE IMPLANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. GCC BIORESORBABLE IMPLANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. GCC BIORESORBABLE IMPLANTS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 315. GCC BIORESORBABLE IMPLANTS MARKET SIZE, BY FIXATION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 316. GCC BIORESORBABLE IMPLANTS MARKET SIZE, BY SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 317. GCC BIORESORBABLE IMPLANTS MARKET SIZE, BY SUTURES, 2018-2032 (USD MILLION)
  • TABLE 318. GCC BIORESORBABLE IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 319. GCC BIORESORBABLE IMPLANTS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 320. GCC BIORESORBABLE IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 321. GCC BIORESORBABLE IMPLANTS MARKET SIZE, BY DENTAL, 2018-2032 (USD MILLION)
  • TABLE 322. GCC BIORESORBABLE IMPLANTS MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 323. GCC BIORESORBABLE IMPLANTS MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 324. GCC BIORESORBABLE IMPLAN